Clicky

FibroGen Inc(1FG)

Description: FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.


Keywords: Biopharmaceutical Chemical Compounds Anemia Pancreatic Cancer Chronic Kidney Disease China Idiopathic Pulmonary Fibrosis Myelodysplastic Syndrome Muscular Dystrophy Liver Fibrosis Treatment Of Idiopathic Pulmonary Fibrosis Diabetic Kidney Disease Roxadustat Hypoxia Inducible Factors Acetic Acids Pamrevlumab Treatment Of Anemia In Chronic Kidney Disease

Home Page: www.fibrogen.com

409 Illinois Street
San Francisco, CA 94158
United States
Phone: 415 978 1200


Officers

Name Title
Mr. Enrique A. Conterno CEO & Director
Mr. Juan Graham Chief Financial Officer
Dr. Elias Kouchakji Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance
Ms. Christine L. Chung Sr. VP of China Operations
Mr. Thane Wettig Exec. VP & Chief Commercial Officer
Dr. Mark Eisner M.D., M.P.H. Exec. VP & Chief Medical Officer
Dr. Barry A. Berkowitz Ph.D. Founder
Dr. John J. Hunter Ph.D. Chief Scientific Officer
Ms. Karen L. Bergman VP of Investor Relations & Corp. Communications
Mr. Michael D. Lowenstein J.D., Ph.D. Chief Legal Officer

Exchange: F

Country: DE

Currency: Euro (€)

Forward PE: 81.3008
Trailing PE: 0
Price-to-Book MRQ: 53.284
Price-to-Sales TTM: 10.3512
IPO Date:
Fiscal Year End: December
Full Time Employees: 566
Back to stocks